# Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

> **NCT05253807** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 8 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT05253807
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-29
- **Primary completion:** 2023-08-16
- **Final completion:** 2023-08-16
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253807, "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05253807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*